411 related articles for article (PubMed ID: 30940536)
1. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
2. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
3. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
4. Enantiomer-specific positive allosteric modulation of CB
Mitjavila J; Yin D; Kulkarni PM; Zanato C; Thakur GA; Ross R; Greig I; Mackie K; Straiker A
Pharmacol Res; 2018 Mar; 129():475-481. PubMed ID: 29158048
[TBL] [Abstract][Full Text] [Related]
5. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
[TBL] [Abstract][Full Text] [Related]
6. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
Thapa D; Cairns EA; Szczesniak AM; Kulkarni PM; Straiker AJ; Thakur GA; Kelly MEM
Molecules; 2020 Jan; 25(2):. PubMed ID: 31968549
[TBL] [Abstract][Full Text] [Related]
7. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
[TBL] [Abstract][Full Text] [Related]
8. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.
Dowie MJ; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2010 Sep; 170(1):324-36. PubMed ID: 20600638
[TBL] [Abstract][Full Text] [Related]
9. The In Vivo Effects of the CB
Cairns EA; Szczesniak AM; Straiker AJ; Kulkarni PM; Pertwee RG; Thakur GA; Baldridge WH; Kelly MEM
J Ocul Pharmacol Ther; 2017 Oct; 33(8):582-590. PubMed ID: 28719234
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
[TBL] [Abstract][Full Text] [Related]
11. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
Garai S; Schaffer PC; Laprairie RB; Janero DR; Pertwee RG; Straiker A; Thakur GA
Bioorg Med Chem; 2021 Nov; 50():116421. PubMed ID: 34634617
[TBL] [Abstract][Full Text] [Related]
13. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.
Roebuck AJ; Greba Q; Smolyakova AM; Alaverdashvili M; Marks WN; Garai S; Baglot SL; Petrie G; Cain SM; Snutch TP; Thakur GA; Hill MN; Howland JG; Laprairie RB
Neuropharmacology; 2021 Jun; 190():108553. PubMed ID: 33845076
[TBL] [Abstract][Full Text] [Related]
14. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.
Dodu JC; Moncayo RK; Damaj MI; Schlosburg JE; Akbarali HI; O'Brien LD; Kendall DA; Wu Z; Lu D; Lichtman AH
J Pharmacol Exp Ther; 2022 Jan; 380(1):1-14. PubMed ID: 34625464
[TBL] [Abstract][Full Text] [Related]
15. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
[TBL] [Abstract][Full Text] [Related]
16. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
17. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
[TBL] [Abstract][Full Text] [Related]
18. CB
Trexler KR; Eckard ML; Kinsey SG
Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
[TBL] [Abstract][Full Text] [Related]
19. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
[TBL] [Abstract][Full Text] [Related]
20. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
